Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27572536 | 0.80 | CA1 (0.45) | CA1CA2ALDH1A1GRM4PKM | |
| SCHEMBL4521506 | 0.80 | CA1 (0.54) | CA1CA2ALDH1A1GRM4PKM | |
| SCHEMBL7775878 | 0.79 | CA1 (0.50) | CA1CA2ALDH1A1GRM4PKM | |
| SCHEMBL7781061 | 0.78 | CA1 (0.46) | CA1CA2ALDH1A1GRM4PKM | |
| SCHEMBL18920634 | 0.78 | ALDH1A1 (0.47) | CA1CA2ALDH1A1GRM4HTR6 | |
| SCHEMBL28748262 | 0.78 | CA1 (0.43) | CA1CA2ALDH1A1GRM4PKM | |
| SCHEMBL4227579 | 0.77 | HTR6 (0.52) | CA1CA2ALDH1A1GRM4PKM | |
| SCHEMBL21806794 | 0.77 | CA1 (0.54) | CA1CA2ALDH1A1GRM4PKM | |
| SCHEMBL18920680 | 0.77 | HTR6 (0.52) | CA1CA2ALDH1A1GRM4PKM | |
| SCHEMBL10050491 | 0.76 | CA1 (0.44) | CA1CA2ALDH1A1GRM4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8092661-B2 | Electropolymerisable monomers, soluble in an aqueous solution and comprising a metalloporphyrin | BIOMERIEUX (FR) | 2012-01-10 | — | — | US | disclosed |
| US-20090314660-A1 | Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin | BIOMERIEUX (FR) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090314660-A1 | Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin | EPS15, PPOX, ACR | CA1 935/4885CA2 1270/4885ALDH1A1 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.